Eli Lilly's GLP-1 Press Release Was Too "Emotive" for the U.K.'s Drug Watchdog
A phrase as small as "transform obesity care" was enough to get Eli Lilly formally reprimanded for promoting an unapproved drug to the British press, and its appeal only made the ruling stick harder.
Eli Lilly learned the hard way that in U.K. pharmaceutical marketing, adjectives count as evidence.
The country's industry self-regulator, the PMCPA, ruled that Eli Lilly breached the marketing code when it sent the BBC a press release covering Phase 3 trial data for orforglipron, its GLP-1 pill now sold as Foundayo, ahead of the drug's marketing approval. A BBC reporter used that release as the basis for a news story, which prompted a complaint. The panel zeroed in on the phrase "transform obesity care," ruling that the language crossed the line from factual disclosure into promotion aimed at a mainstream audience with no medical training to weigh it against, and found that the release brought "discredit upon" the pharmaceutical industry.
Eli Lilly appealed, arguing the panel had "placed undue emphasis on selectively extracted wording" and created "unwarranted uncertainty" for how companies discuss trial data with reporters before approval. The appeal failed. The company's response afterward was notably clipped: "We accept the PMCPA's decision, and we remain committed to upholding our high standards."
The ruling lands in the middle of the loudest, most heavily marketed drug category in a generation, where GLP-1 makers are already sparring over ad claims and racing to plant a flag with every reporter who will take a briefing. A regulator drawing a hard line on pre-approval language is a reminder that the category's marketing arms race has a ceiling, even if the sales numbers do not.
Source: Fierce Pharma
Kyle Duford, Founder & Editor, BRNDWIRE. More from Kyle →
